Search results
Dominik PFISTER, Senior Researcher | Cited by 2,610 | of Novo Nordisk, Copenhagen | Read 32 publications | Contact Dominik PFISTER
24 de mar. de 2021 · Published: 24 March 2021. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Olivier Govaere, Matthias Pinter, Marta...
In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8 + PD1 + T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired.
10 de jun. de 2021 · A recent study published in Nature by Dominik Pfister et al. 1 unveiled a darker side of immune checkpoint blockade (ICB) immunotherapy in the context of nonalcoholic steatohepatitis-associated...
4 de may. de 2021 · “We were interested in how underlying inflammatory liver aetiologies of HCC might impact cancer development and treatment thereof,” say Dominik Pfister and Mathias Heikenwalder, first author...
Dominik Pfister Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20% Modern Pathology
Non-alcoholic fatty liver disease ranges from steatosis to non-alcoholic steatohepatitis (NASH), potentially progressing to cirrhosis and hepatocellular carcinoma (HCC). Here, we show that platelet number, platelet activation and platelet aggregation are increased in NASH but not in steatosis or insulin resistance.
